Stocks
Merck Succeeds in Mid-Stage Trial for Experimental Skin Disease Drug
Merck & Co., Inc. (MRK) has announced success in its mid-stage trial for tulisokibart, an experimental therapy for hidradenitis suppurativa, an inflammatory skin condition.
The company cited data from its Phase 2b trial MK-7240-012 to support the claim, positioning tulisokibart for late-stage development.
Merck's achievement comes after Wednesday's announcement of the mid-stage trial results. The news may have a positive impact on the stock price of MRK.